Cervical cancer screening with HPV testing in the Valcamonica (Italy) screening programme

Journal of Medical Screening

Volumn 22, Issue 1, 2015, Pages 38-48

  Pasquale, L ^a   Giorgi Rossi, Paolo ^b,c   Carozzi, F ^d   Pedretti, C ^a   Ruggeri, C ^a   Scalvinoni, V ^a   Cotti Cottini, M ^a   Tosini, A ^a   Morana, C ^a   Chiaramonte, M ^a   Sacristani, M F ^a   Cirelli, R ^a   Chiudinelli, D ^a   Piccolomini, M ^a   Marchione, R ^a   Romano, L ^a   Domenighini, S ^a   Pieracci, G ^a   Confortini, M ^d  

^a ASL Vallecamonica Sebino   (Italy)

^b PATHOLOGY UNIT   (Italy)

^c S MARIA NUOVA HOSPITAL   (Italy)

^d Istituto Scientifico Prevenzione Oncologica (ISPO)   (Italy)

Author keywords

cervical cancer; Cervical Intraepithelial Neoplasia (CIN); cytology; HPV DNA test; human papilloma virus; mass screening

Indexed keywords

ADULT; ALPHAPAPILLOMAVIRUS; CERVICAL INTRAEPITHELIAL NEOPLASIA; COLPOSCOPY; EARLY DIAGNOSIS; FEMALE; HUMAN; ISOLATION AND PURIFICATION; ITALY; MASS SCREENING; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; PATIENT REFERRAL; PILOT STUDY; PREGNANCY; PREVALENCE; PROCEDURES; UTERINE CERVICAL NEOPLASMS; VIROLOGY;

ADULT; ALPHAPAPILLOMAVIRUS; CERVICAL INTRAEPITHELIAL NEOPLASIA; COLPOSCOPY; EARLY DETECTION OF CANCER; FEMALE; HUMANS; ITALY; MASS SCREENING; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; PILOT PROJECTS; PREGNANCY; PREVALENCE; REFERRAL AND CONSULTATION; UTERINE CERVICAL NEOPLASMS;

EID: 84929331218     PISSN: 09691413     EISSN: 14755793     Source Type: Journal    
DOI: 10.1177/0969141314561707     Document Type: Article

References (32)

1. J.M.WalboomersM.V.JacobsM.M.Manos. Human papillomavirus is a necessary cause of invasivecervical cancer worldwide. J Pathol1999; 189(1): 12–19.
2. IARC, International agency for research on cancer. IARC handbooks of cancer prevention. Cervix Cancer Screening. Vol 10 (2005). Lyon: IARC Press
3. J.CuzickM.ArbynG.Ronco. Overview of human papillomavirusbased and other novel options for cervical cancer screening in developed and developing countries. Vaccine2008a; 26 suppl 10: K29–K41.
4. J.DillnerM.ReboljP.Birembaut. Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ2008; 337: a1754–a1754.
5. P.NauclerW.S.RydA.Tornberg. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med2007; 357: 1589–1597.
6. N.W.BulkmansJ.BerkhofL.Rozendaal. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet2007; 370(9601): 1764–1772.
7. H.C.KitchenerM.AlmonteC.Thomson. HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomised controlled trial. Lancet Oncol2009; 10(7): 672–682.
8. G.P.RoncoF.Giorgi-RossiM.Carozzi. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol2010; 11: 249–257.
9. D.C.RijkaartJ.BerkhofL.Rozendaal. Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial. Lancet Oncol2012; 13(1): 78–88.
10. G.RoncoJ.DillnerK.M.Elfström. Efficacy of HPV-based Screening for Preventing Invasive Cervical Cancer: follow-up of European randomised controlled trials. Lancet2014; 383(9916): 524–532.
11. GISCi, Gruppo Italiano Screening Cervicale. Raccomandazioni sul test HR-HPV come test di screening primario e rivisitazione del ruolo del Pap test. Available on the web (last access 7/5/2014):http://www.gisci.it/documenti/documenti_gisci/documento_hpv.pdf
12. G.RoncoA.BiggeriM.Confortini. Health technology assessment report. Use of liquid-based cytology for cervical cancer precursors screening. Epidemiol Prev2012; 36(5 Suppl 2): e1–33.
13. Health Council of the Netherlands. Population screening for cervical cancer. The Hague: Health Council of the Netherlands, 2011; publication no. 2011/07E
14. NHS-CSP, National Health System Cancer Screening Programs. NHS Cervical Screening Program. HPV primary screening in the NHS Cervical Screening Programme. Available on the web (last access 9/5/2014) at: http://www.cancerscreening.nhs.uk/cervical/hpv-primary-screening.html
15. M.ZorziA.Del MistroA.Farruggio. Use of a high-risk human papillomavirus DNA test as the primary test in a cervical cancer screening programme: a population-based cohort study. BJOG2013; 120(10): 1260–1267.
16. A.Del MistroH.FrayleA.Ferro. Cervical cancer screening by high risk HPV testing in routine practice: results at one year recall of high risk HPV-positive and cytology-negative women. J Med Screen2014; 21(1): 30–37.
17. M.ConfortiniP.Giorgi RossiP.BarbarinoA.M.PassarelliL.OrzellaM.C.Tufi. Screening for cervical cancer with the Human papillomavirus test in an area of central Italy with no previous active cytological screening program. J Med Screen2010; 17(2): 79–86.
18. Gruppo di lavoro GISCi approfondimenti diagnostici e trattamento manuale. Manuale del II livello. Raccomandazioni per la qualità nella diagnosi, terapia e follow up delle lesioni cervicali, nell’ambito dei programmi di screening II livello. Available at (last access 24th July 2014): http://www.gisci.it/documenti/documenti_gisci/Manuale_del_II_Livello.pdf
19. D.SolomonD.DaveyR.Kurman. Bethesda 2001 Workshop. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA2002; 287: 2114–2119.
20. V.A.BouvardR.A.BaanK.A.Straif. Special report: policy. A review of human carcinogens–part B: biological agents. Lancet Oncol2009; 10: 321–322.
21. P.Giorgi RossiF.BaldacchiniG.Ronco. The possible effects on socio-economic inequalities of introducing HPV-testing as primary test in cervical cancer screening programs. Front Oncol2014; 4: 20–20.
22. M.ReboljE.Lynge. Incomplete follow-up of positive HPV tests: overview of randomised controlled trials on primary cervical screening. Br J Cancer2010; 103(3): 310–314.
23. G.RoncoN.SegnanP.Giorgi-Rossi. Human papillomavirus testing and liquid-based cytology: results at recruitment from the new technologies for cervical cancer randomized controlled trial. J Natl Cancer Inst2006; 98(11): 765–774.
24. M.H.MayrandE.Duarte-FrancoI.Rodrigues. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med2007; 357(16): 1579–1588.
25. P.E.CastleM.H.StolerT.C.WrightJrA.SharmaT.L.WrightC.M.Behrens. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study. Lancet Oncol2011; 12(9): 880–890.
26. H.C.KitchenerM.AlmonteC.Gilham. ARTISTIC: a randomised trial of human papillomavirus (HPV) testing in primary cervical screening iii-iv. Health Technol Assess2009; 13(51): 1–150.
27. A.C.RodríguezM.SchiffmanR.Herrero. Longitudinal study of human papillomavirus persistence and cervical intraepithelial neoplasia grade 2/3: critical role of duration of infection. J Natl Cancer Inst2010; 102(5): 315–324.
28. A.NielsenS.K.KjaerC.MunkM.OslerT.Iftner. Persistence of high-risk human papillomavirus infection in a population-based cohort of Danish women. J Med Virol2010; 82(4): 616–623.
29. G.RoncoP.Giorgi-RossiF.Carozzi. Human papillomavirus testing and liquid-based cytology in primary screening of women younger than 35 years: results at recruitment for a randomised controlled trial. Lancet Oncol2006; 7: 547–555.
30. P.SasieniA.CastanonJ.Cuzick. Effectiveness of cervical screening with age: population based case-control study of prospectively recorded data. BMJ2009; 339: b2968–b2968.
31. Sasieni P, Castanon A, Cuzick J. The impact of cervical screening on young women: a critical review of the literature 2002–2009. NHSCSP Publication No 31 February 2010
32. S.LönnbergA.AnttilaT.LuostarinenP.Nieminen. Age-specific effectiveness of the Finnish cervical cancer screening programme. Cancer Epidemiol Biomarkers Prev2012; 21(8): 1354–1361.